Overview

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Status:
Not yet recruiting

Trial end date:
2024-12-06

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to see how useful it is to look at biomarkers in the blood and tumor tissue of participants with ovarian, fallopian tube or primary peritoneal cancer who have previously received treatment with a drug called a PARP inhibitor, and using the results to determine the best treatment for these participants. Biomarkers are molecules such as genes (molecules that contain instructions for the development and function of cells in the body) and proteins that may be used to see how well a body responds to certain treatments.

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Collaborator:

GlaxoSmithKline

Treatments:

Bevacizumab
Niraparib
Paclitaxel